• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Okusaka, T.
    Kitano, M.
    Chen, M.
    Chen, J.
    Ostwal, V.
    McNamara, Mairead G
    Breder, V.
    Petrova, M.
    Buchschacher, G.
    Rokutanda, N.
    Xiong, J.
    Cohen, G.
    Oh, D.
    Show allShow less
    Affiliation
    National Cancer Center Hospital, Tokyo, Japan; 2Wakayama Medical University,Wakayama, Japan;
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Background: TOPAZ-1 (NCT03875235) was a randomised, double-blind, global, phase 3 study evaluating the efficacy and safety of durvalumab plus gemcitabine and cisplatin (durvalumab) as first-line treatment for patients with advanced biliary tract cancer (BTC; Oh D-Y, et al. J Clin Oncol 2022;40[suppl 4]. Abs 378). Durvalumab significantly improved overall survival (OS) versus placebo plus gemcitabine and cisplatin (placebo) and represents a potential new treatment option for patients with advanced BTC. In BTC, disease status at baseline (initially unresectable vs recurrent [>6 months after surgery with curative intent or >6 months after adjuvant therapy]) may impact response to treatment. Methods: The aim of this exploratory subgroup analysis of TOPAZ-1 was to assess efficacy outcomes by disease status at baseline in patients receiving durvalumab versus placebo. Patients with BTC were randomised 1:1 to receive durvalumab (1500 mg) or placebo on Day 1 Q3W, plus gemcitabine (1000 mg/m2) and cisplatin (25 mg/ m2) on Day 1 and 8 Q3W, for up to 8 cycles, followed by durvalumab or placebo monotherapy until disease progression, unacceptable toxicity or other discontinua- tion criteria were met. Randomisation was stratified by disease status and primary tumour location (intrahepatic cholangiocarcinoma vs extrahepatic chol- angiocarcinoma vs gallbladder cancer). Subgroup analysis of OS, progression-free survival (PFS), objective response rate (ORR) and duration of response (DoR) per RECIST v1.1 by disease status at baseline (initially unresectable or recurrent) was performed. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for OS and PFS using a Cox proportional hazards model, and odds ratios (ORs) and 95% CIs for ORR were calculated using the Cochran-Mantel Haenszel test. Results: The study included more patients with initially unresectable than recurrent disease (durvalumab, n¼274 [80.4%] vs n¼67 [19.6%]; placebo, n¼279 [81.1%] vs n¼64 [18.6%]). HRs for OS favoured durvalumab for both initially unresectable (0.84; 95% CI, 0.69e1.03) and recurrent (0.56; 95% CI, 0.32e0.96) disease; HRs for PFS also favoured durvalumab in both subgroups (0.79; 95% CI 0.66e0.95 and 0.63; 95% CI 0.42e0.94, respectively). ORs for ORR favoured durvalumab for both initially unre- sectable (1.61; 95% CI, 1.06e2.45) and recurrent (1.52; 95% CI 0.73e3.18) disease. Median DoR for durvalumab versus placebo was 6.0 versus 5.1 months for initially unresectable, and 9.7 versus 7.9 months for recurrent disease. Percentage of re- sponders with a DoR of at least 9 and 12 months was numerically higher with dur- valumab versus placebo for both initially unresectable (9-month, 21.5% vs 20.3%; 12- month, 16.7% vs 10.7%) and recurrent (9 months, 58.8% vs 38.1%; 12 months, 48.1% vs 25.4%) disease. Conclusions: In TOPAZ-1, addition of durvalumab to GemCis improved efficacy out- comes both in patients with initially unresectable and patients with recurrent disease at baseline, though the relative benefit versus placebo appears greater for recurrent compared with initially unresectable disease. These findings support the use of dur- valumab plus GemCis as a potential new treatment option for patients with advanced BTC, irrespective of disease status.
    Citation
    Okusaka T, Kitano M, Chen M, Chen J, Ostwal V, McNamara M, et al. Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study. Annals of Oncology. 2022 Jun;33:S242-S. PubMed PMID: WOS:000823826500009.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/625586
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.